NYSE American - Nasdaq Real Time Price USD

iBio, Inc. (IBIO)

1.9000 0.0000 (0.00%)
As of 9:51 AM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
6/30/2023
6/30/2022
6/30/2021
6/30/2020
Total Revenue
50.0000
--
1,884.0000
2,371.0000
1,638.0000
Cost of Revenue
--
--
216.0000
1,462.0000
703.0000
Gross Profit
--
--
2,167.0000
909.0000
935.0000
Operating Expense
20,783.0000
29,343.0000
31,581.0000
32,020.0000
14,938.0000
Operating Income
-20,733.0000
-29,343.0000
-29,697.0000
-31,111.0000
-14,003.0000
Net Non Operating Interest Income Expense
58.0000
130.0000
177.0000
-2,314.0000
-2,451.0000
Other Income Expense
--
-98.0000
7.0000
10,212.0000
10.0000
Pretax Income
-20,773.0000
-29,311.0000
-29,513.0000
-23,213.0000
-16,444.0000
Net Income Common Stockholders
-27,284.0000
-65,010.0000
-50,391.0000
-23,467.0000
-38,260.0000
Diluted NI Available to Com Stockholders
-27,284.0000
-65,010.0000
-50,391.0000
-23,467.0000
-38,260.0000
Basic EPS
-4.50
-106.20
-115.60
-60.00
-305.00
Diluted EPS
-4.50
-106.20
-115.60
-60.00
-305.00
Basic Average Shares
1,141.7500
612.2500
436.0500
391.2500
125.5900
Diluted Average Shares
3,243.7250
612.2500
436.0500
391.2500
125.5900
Total Operating Income as Reported
-20,733.0000
-29,343.0000
-29,697.0000
-31,111.0000
-14,003.0000
Total Expenses
20,783.0000
29,343.0000
31,581.0000
33,482.0000
15,641.0000
Net Income from Continuing & Discontinued Operation
-27,284.0000
-65,010.0000
-50,303.0000
-23,207.0000
-16,439.0000
Normalized Income
-20,675.0000
-29,213.0000
-29,512.0000
-33,407.0000
-16,439.0000
Interest Income
170.0000
213.0000
177.0000
140.0000
15.0000
Interest Expense
112.0000
83.0000
--
2,454.0000
2,466.0000
Net Interest Income
58.0000
130.0000
177.0000
-2,314.0000
-2,451.0000
EBIT
-20,661.0000
-29,228.0000
-29,513.0000
-20,759.0000
-13,978.0000
EBITDA
-19,437.0000
-27,848.0000
-25,722.0000
-18,345.0000
-11,737.0000
Reconciled Cost of Revenue
--
--
216.0000
1,462.0000
703.0000
Reconciled Depreciation
1,224.0000
1,380.0000
3,791.0000
2,414.0000
2,241.0000
Net Income from Continuing Operation Net Minority Interest
-20,773.0000
-29,311.0000
-29,512.0000
-23,207.0000
-16,439.0000
Total Unusual Items Excluding Goodwill
-98.0000
-98.0000
607.0000
10,200.0000
--
Total Unusual Items
-98.0000
-98.0000
607.0000
10,200.0000
--
Normalized EBITDA
-19,339.0000
-27,750.0000
-25,722.0000
-28,545.0000
-11,737.0000
6/30/2020 - 8/19/2008

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AVTX Avalo Therapeutics, Inc.
14.29
+0.63%
 
ADIL Adial Pharmaceuticals, Inc.
1.7100
0.00%
 
TNXP Tonix Pharmaceuticals Holding Corp.
0.1581
-1.19%
 
VXRT Vaxart, Inc.
0.7040
-0.80%
 
JAGX Jaguar Health, Inc.
0.1614
-5.00%
 
LGVN Longeveron Inc.
1.6199
-5.85%
 
CADL Candel Therapeutics, Inc.
5.86
-3.14%
 
BPTH Bio-Path Holdings, Inc.
2.4250
-3.00%
 
NKGN NKGen Biotech, Inc.
1.8513
+8.17%
 
XLO Xilio Therapeutics, Inc.
1.0300
-2.80%